retatrutide triple agonist phase 2 nejm 2023 obesity results Agonism Based Therapies for | Current Cardiovascular Risk Reports The trial that put “24%”

Myo-inositol alone or in combination with D-chiro-inositol significantly reduced weight, BMI, and waist-hip circumference ratios in overweight/obese women with PCOS

It causes your body to produce more insulin lowers your blood sugar suppresses your appetite The READ NEXT: How to get semaglutide Yes

Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides

If semaglutide proves effective, it would be the first drug originally approved for another condition to be repurposed and made widely available for Alzheimer's treatment

GLP-1 medications like compounded semaglutide and tirzepatide aren't for everyone but for the right patient, with the right supervision, they can be genuinely life-changing